Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan:138:109034.
doi: 10.1016/j.yebeh.2022.109034. Epub 2022 Dec 14.

Status epilepticus in pregnancy

Felix Rosenow  1 , Catrin Mann  2
Affiliations
Review

Status epilepticus in pregnancy

Felix Rosenow et al. Epilepsy Behav. 2023 Jan.

Abstract

Status epilepticus is a frequent neurological emergency associated with a case fatality of about 10-15% depending on age, cause, and other factors, and a high burden for patients, caregivers, and society. In pregnancy, it can occur in two different clinical constellations: (1) In women with a history of epilepsy and (2) as new onset status epilepticus in pregnancy (NOSEP). Both entities are relatively rare but differ in terms of etiology. Here we describe the epidemiology, etiologies, diagnosis, clinical course with the maternal and fetal outcome, and the suggested management strategies for either manifestation. This paper was presented at the 8th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures held in September 2022.

Keywords: Antiseizure medication; Eclampsia; Epilepsy; PRES; RCVS; Seizures.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: FR is leading author of the German guidelines on status epilepticus in adults. He received honoraria from Angelini Pharma/Arvelle Therapeutics, Eisai GmbH, GSK, GW Pharmaceuticals/Jazz Pharma, MedilearnIndia, Roche Pharma, UCB Pharma/Zogenix, and grants from Eisai GmbH, Federal State of Hesse, Germany, through the LOEWE programme, Grants from the German Research Foundation (DFG), the European Union (FP7), the Detlev-Wrobel Fonds for Epilepsy Research, Frankfurt, The CHAJA Foundation Frankfurt, and the German Minister for Education and Research (BMBF), Dr. Schär GmbH, Vitaflo GmbH, Nutricia Milupa GmbH, and Desitin Arzneimittel GmbH. CM reports speakers’ honoraria from Eisai and travel support from GW Pharmaceuticals and Zogenix, outside of the submitted work.

LinkOut - more resources